Separation Solutions to Accelerate Next Generation Gene Therapy Development

Significance of Gene Therapy Analytical Methods

Gene therapy products such as viral vectors, lipid nanoparticles, oligonucleotides and mRNA are highly complex and sensitive. Accurate characterization of critical quality attributes (CQAs) is essential to ensure product safety, efficacy and regulatory compliance. Robust, high‐throughput analytical workflows reduce development timelines and help translate promising therapies from bench to clinic.

Objectives and Overview of Waters’ Approach

This whitepaper addresses three common analytical challenges in gene therapy development:

• Maximizing information from limited, precious samples.
• Accelerating method development with scalable, transferable platforms.
• Obtaining reliable data under tight timelines.

Waters proposes a comprehensive suite of columns, consumables and informatics solutions tailored to each modality—AAV, adenovirus, lipid nanoparticles, oligonucleotides, mRNA and plasmid DNA.

Methodology and Used Instrumentation

Analytical strategies combine liquid chromatography (LC) techniques (SEC, reversed‐phase, ion‐exchange, ion‐pairing, HILIC) with compatible column chemistries and dimensions:

• ACQUITY Premier platforms with Protein BEH, BEH C4, Oligonucleotide BEH C18 phases.
• BioAccord LC-MS system for intact mass, peptide mapping and nucleic acid mass confirmation.
• MaxPeak High Performance Surfaces (HPS) columns featuring inert surfaces to prevent non-specific adsorption.
• IonHance and RapiGest surfactants to improve protein recovery and digestion efficiency.
• Scalable column particles (1.7 µm to 5 µm) enabling method transfer from discovery to QC.

Main Results and Discussion

Key findings from application notes and development case studies include:

• Inert-surface columns significantly reduce sample loss in SEC and affinity-based workflows, improving sensitivity and reproducibility.
• Sub-2 µm particle columns on UPLC systems deliver high peak capacity and faster run times for intact capsid analysis and peptide mapping of AAV.
• Ion-pairing RPLC and HILIC methods enable rapid, high‐resolution separation of oligonucleotides and mRNA cap variants with reliable mass confirmation.
• Anion-exchange chromatography coupled to fluorescence or evaporative light scattering detection effectively resolves plasmid isoforms and dsDNA fragments.
• Automated informatics solutions streamline data processing and reporting, ensuring compliance and accelerating decision‐making.

Benefits and Practical Applications

These integrated solutions offer:

• High sensitivity and minimal sample consumption for characterizing low-abundance species.
• Scalable methods that move seamlessly from research through regulatory QC.
• Rapid turnaround times—critical for time-sensitive clinical candidates.
• Enhanced data confidence through end-to-end informatics and technical support.

Future Trends and Opportunities

Emerging directions in gene therapy analytics include:

• Further miniaturization and microflow LC to conserve samples and increase MS sensitivity.
• Integration of multi‐attribute methods (MAM) combining intact mass, attribute quantitation and host-cell impurity profiles in a single run.
• Advanced AI‐driven data analysis for pattern recognition in complex datasets.
• Hybrid workflows combining LC, capillary electrophoresis and orthogonal MS techniques for comprehensive characterization.

Conclusion

Waters’ portfolio of inert‐surface columns, scalable UPLC particles and compliance-ready informatics addresses key analytical challenges in gene therapy development. By optimizing sample handling, accelerating method development and automating data workflows, researchers can generate robust, reproducible data faster and with greater confidence, ultimately supporting the advancement of next-generation therapeutics.

Reference

No external literature references were provided in the original text.